The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2022WATCH-PD Remote Digital Health Technology Extension: Planning Period
Study Rationale: In the WATCH-PD study, we evaluated the use of wearable digital devices to monitor symptoms and quality of life in individuals with early, untreated Parkinson’s disease (PD). This...
-
Research Grant, 2022Identifying Bothersome Symptoms, Impacts of Disease and Relevance of WATCH-PD Digital Measures Over Time in Early Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is a devastating neurologic disease and current treatments are unable to prevent the worsening of symptoms. One problem in developing new therapies has been...
-
Research Grant, 2023Ensuring Diversity and Equity in Parkinson’s Disease Research and Care
Study Rationale: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders across the world. PD has a negative impact on a person’s mobility and their ability to carry out...
-
Biomarkers to Support Therapeutic Trials Program, 2023Analyzing the Aggregation Properties of Alpha-synuclein in Different Genetic Subtypes of Parkinson’s Disease
Study Rationale: Abnormal clumping of alpha-synuclein appears to be an important cause for the death of dopamine cells in Parkinson disease (PD). Recent studies discovered that small amounts of tiny...
-
Research Grant, 2023Evaluating a Gene Therapy that Restores Mitochondrial Function as a Treatment for Parkinson’s Disease
Study Rationale: Currently, all treatments for Parkinson’s disease (PD) aim to improve symptoms by restoring or maintaining the levels of dopamine in the brain. No treatment on the market slows or...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program - Therapeutics, 2023Assessing the Ability of Dapansutrile, a Selective, Oral Inhibitor of the NLRP3 Neuroinflammatory Pathway, to Mitigate Progression of Parkinson’s Disease
Study Rationale: Increasing scientific data indicate the role of neuroinflammation in the pathology of Parkinson’s disease (PD) and related alpha-synucleinopathies. Dapansutrile (lab code: OLT1177®...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.